Chronic Myeloid Leukemia: Current Guidelines for Diagnosis and Management

References

• Silver, R. T. (1990). Chronic myeloid leukemia. A. perspective of the clinical and biologic issues of the chronic phase. Hematol. Oncol. Clin. North. Am., 4, 319–335.
   PubMed Web of Science ®Google Scholar
• Champlin, R. E. and Golde, D. W. (1985). Chronic myelogenous leukemia: recent advances. Blood, 65, 1039–1047.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., Deisseroth, A., Kurzrock, R., Estrov, Z. and Talpaz, M. (1993). Chronic myelogenous leukemia: a concise update. Blood, 82, 691–703.
   PubMed Web of Science ®Google Scholar
• Pialkow, P. J., Jacobson, R. J. and Papayannopoulou, T. (1977). Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med., 63, 125–130.
   PubMed Web of Science ®Google Scholar
• Pialkow, P. J., Gartler, S. M. and Yoshida, A. (1967). Clonal origin of chronic myelocytic leukemia in man. Proc. Natl. Acad. Sci. USA, 58, 1468–1471.
   PubMed Web of Science ®Google Scholar
• Morrison, V. A. (1994). Chronic leukemias. CA Cancer J. Clin., 44, 353–377.
   PubMed Web of Science ®Google Scholar
• Brincker, H. (1982). Population based aged and sex specific incidence rates in the 4 main types of leukaemias. Scand. J. Haematol, 29, 241–249.
   PubMedGoogle Scholar
• Call, T. G., Noel, P., Habermann, T. M., Beard, C. M., O'Fallon, M. and Kurland, L. T. (1994). Incidence of leukemia in Olmsted county, Minnesota, 1975 through 1989. Mayo Clin. Proc., 69, 315–322.
   PubMed Web of Science ®Google Scholar
• Hughes, T. P. and Goldman, J. M. (1991). Chronic myeloid leukemia. In.: Hoffman, R., Benz, E. J. and Shattil, S. J.., Haematology. Basic. Principles and Practice, New York: Churchill Livingstone, pp. 854–869.
   Google Scholar
• Moloney, W. C. (1977). Natural history of chronic granulocytic leukaemia. Clin. Haematol., 6, 41–60.
   PubMedGoogle Scholar
• Baranovsky, A. and Myers, M. H. (1986). Cancer incidence and survival in patients 65 years and older. CA Cancer J. Clin., 36, 26–41.
   PubMed Web of Science ®Google Scholar
• Nowell, P. C. and Hungerford, D. A. (1960). A minute chromosome in human chronic granulocytic leukemia. Science, 132, 1497.
   Web of Science ®Google Scholar
• Rowley, J. D. (1973). A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, 290–293.
   PubMed Web of Science ®Google Scholar
• Kurzrock, R., Guttermann, J. U. and Talpaz, M. (1988). The molecular genetics of Philadelphia chromosome-positive leukemias. New Eng. J. Med., 319, 990–998.
   PubMed Web of Science ®Google Scholar
• Heisterkamp, N., Stephenson, J. R., Groffen, J., et al. (1983). Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature, 306, 239–242.
   PubMed Web of Science ®Google Scholar
• Konopka, J. B. and Witten, O. N. (1985). Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol. Cell. Biol., 5, 3116–3123.
   PubMed Web of Science ®Google Scholar
• Heisterkamp, N., Stam, K., Groffen, J., de Klein, A. and Grosveld, G. (1985). Structural organization of the bcr gene and its role in the Ph translocation. Nature, 315, 758–761.
   PubMed Web of Science ®Google Scholar
• Gordon, M. Y. (1996). Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment. Brit. J. Heamatol, 95, 10–20.
   PubMed Web of Science ®Google Scholar
• Melo, J. V. (1996). The molecular biology of chronic myeloid leukemia. Leukemia, 10, 751–756.
   PubMed Web of Science ®Google Scholar
• Hochhaus, A. et al. (1995). Atypical BCR-ABL transcripts in chronic myelogenous leukemia (CML) patients detected by multiplex polymerase chain reaction. Blood, 86 (Suppl. 1), 526a.
   Google Scholar
• van der Plas, D. C. et al. (1991). bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogenous luekemia. Luekemia, 5, 457–461.
   PubMed Web of Science ®Google Scholar
• Iwata, S., Mizutani, S., Nakazawa, S. and Yata, J. (1994). Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. Luekemia, 8, 1696–1702.
   PubMed Web of Science ®Google Scholar
• Gale, R. P. and Cannani, E. (1984). An 8-kilobase abl RNA transcript in chronic myelogenous leukemia. Proc. Natl. Acad. Sci. USA, 81, 5648–5652.
   PubMed Web of Science ®Google Scholar
• Preti, H. A., O'Brain, S., Giralt, S., Beran, M., Pierce, S. and Kantarjian, H. (1994). Philadelphia-chromosomepositive adult acute lymphocytic leukemia: characteristics, treatment results and prognosis in 41 patients. Am. J. Med., 97, 60–65.
   PubMed Web of Science ®Google Scholar
• Clark, S. C., McLaughlin, J. and Crist, W. M. (1987). Unique forms of the abl tyrosine kinase distinguish Ph-positive actue lymphocytic leukaemia. Nature, 325, 635–637.
   PubMedGoogle Scholar
• Melo, J. V., Myint, H., Galton, D. A. G. and Goldman, J. M. (1994). P190 BCR-ABL chronic myeloid leukemia: The missing link with chronic myelomonocytic leukemia? Leukemia, 8, 208–211.
   PubMed Web of Science ®Google Scholar
• Pane, F., Frigeri, F., Sinodna, M. et al. (1996). Neutrophilic chronic myeloid luekemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood, 88, 2410–2414.
   PubMed Web of Science ®Google Scholar
• Konopka, J. B., Watanabe, S. M. and Witte, O. N. (1984). An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell, 37, 1035–1042.
   PubMed Web of Science ®Google Scholar
• Kloetzer, W., Kurzrock, R., Smith, L. et al. (1985). The human cellular abl gene product in chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology, 140, 230–238.
   PubMed Web of Science ®Google Scholar
• Kurzrock, R., Kloetzer, W. S., Talpaz, M. et al. (1987). Identification of molecular variants of p210 bcr-abl in chronic myelogenous leukemia. Blood, 70, 233–236.
   PubMed Web of Science ®Google Scholar
• Konopka, J. B. and Witte, O. N. (1985). Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol. Cell. Biol., 5, 3116–3123.
   PubMed Web of Science ®Google Scholar
• Daley, G. Q., Van Etten, R. A. and Baltimore, D. (1990). Induction of chronic myelogenous leukemia in mice by the p210 bcr-abl gene of the Philadelphia chromosome. Science, 247, 824–830.
   PubMed Web of Science ®Google Scholar
• Kelliher, M. A., McLaughlin, J., Witte, O. N. and Rosenberg, N. (1990). Induction of a chronic myelogeneous leukemia-like syndrome in mice with v-abl and BCR-ABL. Proc. Natl. Acad. Sci. USA, 87, 6649–6653.
   PubMed Web of Science ®Google Scholar
• Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P. K. and Groffen, J. (1990). Acute leukaemia in bcr/abl transgenic mice. Nature, 344, 251–253.
   PubMed Web of Science ®Google Scholar
• Lewis, J. M., Baskaran, M., Taagepera, S. et al. (1996). Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic nuclear transport. Proc. Natl. Acad. Sci. USA, 93, 15174–15179.
   PubMed Web of Science ®Google Scholar
• Sattler, M., Saliga, R., Okuda, K. et al. (1996). The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190 BCR/ABL and p210 BCR/ABL to the phosphatidylinositol-3 kinase pathway. Oncogene, 12, 839–946.
   PubMed Web of Science ®Google Scholar
• Saliga, R., Pisick, E., Sattler, M. et al. (1996). P130CAS forms a signaling complex with the adaptor proteins CRKL in hematopoietic cells transformed by the BCR-ABL oncogene. J. Biol. Chem., 271, 25198–25203.
   PubMed Web of Science ®Google Scholar
• Caprino, N., Wisniewski, D. et al. (1997). p62DOK: A constitutively tyrosine phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell, 88, 197–204.
   PubMed Web of Science ®Google Scholar
• Yamanashi, Y. and Baltimore, D. (1997). Identification of the rasGAP associated 62 kDA protein as a docking protein, Dok. Cell, 88, 205–211.
   PubMed Web of Science ®Google Scholar
• Verfaillie, C. M., Hurley, R., Lundell, B. I., Zhao, C. and Bahatia, R. (1996). Integrin-mediated regulation of haematopoiesis: Do BCR/ABL induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Acta Haematol., 97, 40–52.
   Web of Science ®Google Scholar
• Melo, J. V., Gordon, D. E., Cross, N. C. P. and Goldman, J. M. (1993). The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood, 81, 158–165.
   PubMed Web of Science ®Google Scholar
• Potter, A. M. and Watmore, A. (1992). Cytogenetics in myeloid leukaemia. In: Rooney, D. E. and Czepulkowski B. H., Human Cytogenetics, Vol II. Oxford University Press, 27–66.
   Google Scholar
• Ahuja, H., Bar-Eli, M., Arlin, Z. et al. (1991). The spectrum of molecular alterations in the evolution of chronic myeloid leukemia. J. Clin. Invest., 87, 2042–2047.
   PubMed Web of Science ®Google Scholar
• Wetzler, M., Talpaz, M., Estrov, Z. and Kurzrock, R. (1993). CML: mechanisms of initiation and progression. Leuk. Lymphoma., 11, (Suppl. 1), 47–50.
   PubMedGoogle Scholar
• Feinstein, E. et al. (1991). p53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. USA, 88, 6293–6297.
   PubMed Web of Science ®Google Scholar
• Sawyers, C. (1993). The role of MYC in transformation by BCR-ABL. Leuk. Lymphoma., 11, (Suppl. 1), 45–46.
   PubMed Web of Science ®Google Scholar
• Jennings, B. (1995). A study of changes in methylation status and copy number at the c-myc locus during progression of chronic myeloid leukaemia. Br. J. Haematol., 89, (Suppl. 1), 37.
   Google Scholar
• Ahuja, H. G., Jat, P. S., Foti, A., Bar-Eli, M. and Cline, M. J. (1991). Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood, 78, 3259–3268.
   PubMed Web of Science ®Google Scholar
• Towatari, M., Adachi, K., Kato, H. and Saito, H. (1991). Absence of the human retinoblastoma gene product in the megakaryocytic crisis of chronic myelogenous leukemia. Blood, 78, 2178–2181.
   PubMed Web of Science ®Google Scholar
• Sill, H., Goldman, J. M. and Cross, N. C. P. (1995). Homozygous deletions of the p16 tumor suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood, 85, 2013–2016.
   PubMed Web of Science ®Google Scholar
• Cogswell, P. C. et al. (1989). Mutations of the Ras protooncogenes in chronic myelogenous leukemia: a high frequency of Ras mutations in bcr-abl negative chronic myelogenous leukemia. Blood, 74, 2629–2633.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., Dixon, D., Keating, M. J. et al. (1988). Characteristics of accelerated disease in chronic myelogeneous leukemia. Cancer, 61, 1441–1446.
   PubMed Web of Science ®Google Scholar
• Cramer, E., Auclair, C., Hakim, J. et al. (1977). Metabolic activity of phagocytosing granulocytes in chronic granulocytic leukemia: ultrastructural observation of a degranulation defect. Blood, 50, 93–106.
   PubMed Web of Science ®Google Scholar
• Goldman, J. M. and Marks, D. I. (1995). Chronic myelogenous leukemia. In: Blood: Principles and Practice of Hematology; Handin, pp. 457–474.
   Google Scholar
• Know, W. F., Bhavnani, M., Davson, J. and Geary, C. G. (1984). Histological classification of chronic granulocytic leukemia. Clin. Lab. Haematol., 6, 171–175.
   PubMedGoogle Scholar
• Rosner, F., Schreiber, Z. R. and Parise, F. (1972). leukocyte alkaline phosphatase. Arch. Int. Med., 130, 892–894.
   PubMedGoogle Scholar
• Rustin, G. J. S., Goldman, J. M., McCarthy, D., Mees, S. and Peters, T. J. (1980). An extrinsic factor controls neutrophil alkaline phosphatase synthesis in chronic granulocytic leukaemia. Br. J. Haematol., 45, 381–387.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., Keating M. J., Talpaz, M. et al., (1987). Chronic myelogenous leukemia in blast crisis. Analysis. of 242 patients. Am. J. Med., 83, 445–454.
   PubMed Web of Science ®Google Scholar
• Jacknow, G., Frizzera, G., Gail-Peczalska, K. et al. (1985). Extramedullary presentation of the blast crisis of chronic myelogenous leukaemia. Br. J. Haematol., 61, 225–236.
   PubMed Web of Science ®Google Scholar
• Terjanian, T., Kantarjian, H., Keating, M., Talpaz, M., McCredie, K. and Freireich, E. J. (1987). Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease. Cancer, 59, 297–300.
   PubMed Web of Science ®Google Scholar
• Derderian, P. M., Kantarjian, H. M., Talpaz, M. et al. (1993). Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am. J. Med., 94, 69–74.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., Dixon, D., Keating M. J. et al. (1988). Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer, 61, 1441–1446.
   PubMed Web of Science ®Google Scholar
• Majlis, A., Smith, T. L., Talpaz, M., O'Brien, S., Rios, M. B. and Kantarjian, H. M. (1996). Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J.. Clin. Oncol., 14, 196–203.
   Web of Science ®Google Scholar
• Tura, S., Baccarani, M. and Corbelli, G. (1981). The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Staging. of chronic myeloid leukaemia. Br. J. Haematol., 47, 105–119.
   PubMed Web of Science ®Google Scholar
• Cervantes, F. and Rozman, C. (1982). A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood, 60, 1298–1304.
   PubMed Web of Science ®Google Scholar
• Sokal, J. E., Cox, E. B., Baccarani, M. et al. (1984). Prognostic discrimination in “good risk” chronic granulocytic leukemia. Blood, 63, 789–799.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., Smith, T. L., McCredie, K. B. et al. (1985). Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood, 66, 1326–1335.
   PubMed Web of Science ®Google Scholar
• Sokal, J. E., Baccarani, M., Tura, S. et al. (1985). Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood, 66, 1352–1357.
   PubMed Web of Science ®Google Scholar
• Oguma, S., Takatsuki, K., Uchino, H., Kamada, N., Oguma, N. and Kuramoto, A. (1982). Factors influencing survival in Philadelphia chromosome-positive chronic myelocytic leukemia. Cancer, 50, 2928–2934.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., Keating, M. J., Smith, T. L. and Talpaz, M. (1990). Proposal for a simple staging system in chronic myelogenous leukemia. Am. J. Med., 88, 1–8.
   PubMed Web of Science ®Google Scholar
• Hehlmann, R., Heimpel, H., Hasford, J. et al. (1993). Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood, 83, 398–407.
   Google Scholar
• Robertson, M. J., Tantravahi, R., Griffin, J. D., Canellos, G. P. and Cannistra, S. A. (1993). Haematologic remission and cytogenetic improvement after treatment of stable phase chronic myelogenous leukemia with continuous infusion of low dose cytarabine. Am. J. Hematol., 43, 95–102.
   PubMed Web of Science ®Google Scholar
• Renner, D., Queisser, U., Martinez, C. and Queisser, W. (1987). Treatment of excessive thrombocytopenia in chronic myeloid leukemia by thrombocytopheresis and intravenous Thio-TEPA. Onkologie, 10, 324–326.
   PubMedGoogle Scholar
• Chinese People's Liberation Army 187th hospital: Harringtonine in acute leukemia: Clinical analysis of 31 cases. (1977) Chin. Med. J., 3, 319.
   PubMed Web of Science ®Google Scholar
• Chinese People's Liberation Army 187th hospital: Harringtonine in the treatment of acute leukemia: Clinical analysis of 72 cases. (1978) Chin. Med. J., 3, 163.
   Google Scholar
• O'Brien, S., Kantarjian, H. M., Feldman, E. et al. (1992). Homoharringtonine produces high hematologic and cytogenetic response rates in Philadelphia chromosome positive chronic myelogenous leukemia. Blood, 80, (Suppl. 1), 358 (abstract).
   Google Scholar
• O'Brien, S., Kantarjian, H. M., Keating, M. J., Talpaz, M. et al. (1995). Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood, 86, 3322–3325.
   PubMed Web of Science ®Google Scholar
• Issa, J.-P., Baylin, S. G. and Herman, J. G. (1997). DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia, 11, (Suppl. 1), 7–11.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., O'Brien, S. M., Keating, M., Beran, M., Estey, E., Giralt, S. et al. (1997). Results of decitabine therapy in the accelerated and blastic phase of chronic myelogenous leukemia. Leukemia, 11, 1617–1620.
   PubMed Web of Science ®Google Scholar
• Talpaz, M., McCredie, K. B., Trujillo, J., Mavligit, G. M. and Gutterman, J. U. (1983). Leukocyte interferon induced myeloid cytoreduction in chronic myelogenous leukemia. Blood, 62, 689–692.
   PubMed Web of Science ®Google Scholar
• Talpaz, M., Kantarjian, H. M., McCredie, K. B., Gutterman, J. et al. (1987). Clinical investigation of human alfa interferon in chronic myelogenous leukemia. Blood, 69, 1280–1288.
   PubMed Web of Science ®Google Scholar
• Talpaz, M., Kantarjian, H. M., McCredie, K. B., Gutterman, J. et al. (1986). Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha, in chronic myelogenous leukemia. N. Eng. J. Med., 314, 1065–1069.
   PubMed Web of Science ®Google Scholar
• Niederle, N., Kloke, O., May, D. et al. (1987). Treatment of chronic myelogenous leukemia with recombinant interferon alpha-2b. Invest. New. Drugs, 5, 19.
   Web of Science ®Google Scholar
• Alimena, G., Morra, E., Lazzarino, M. et al. (1988). Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia. A. study of 82 patients treated with intermittent or daily administration. Blood, 72, 642.
   PubMed Web of Science ®Google Scholar
• Aulitzky, W. E., Peschel, C., Schneller, F. and Huber, C. (1995). Biotherapy of chronic myelogenous leukemia. Ann. Hematol., 70, 113–120.
   PubMed Web of Science ®Google Scholar
• Broxmeyer, H. E., Lu, E., Platzer, E., Feit, C., Juliano, L. and Rubin, B. Y. (1983). Comparative analyses of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte macrophage (CFU-GM) progenitor cells. J. Immunol., 131, 1300–1309.
   PubMed Web of Science ®Google Scholar
• Gordon, M. Y., Dowding, C. R., Riley, G. P., Goldman, J. M. and Greaves, M. F. (1987). Altered adhesive interaction with bone marrow stroma of haematopoetic progenitor cells in chronic myelogenous leukemia. Nature, 328, 342–344.
   PubMed Web of Science ®Google Scholar
• Gordon, M. Y., Atkinson, J., Clarke, D., Dowding, C. R., Goldman, J. M., Greaves, M. F. et al. (1991). Deficiency of a phosphatidylinositol-anchored cell adhesion molecule influences haemopoietic progenitor binding to marrow stroma in chronic myeloid leukemia. Leukemia, 5, 693–698.
   PubMed Web of Science ®Google Scholar
• Dowding, C., Guo, A. P., Gordon, M. et al. (1991). Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stomal cells. Blood, 78, 499–505.
   PubMed Web of Science ®Google Scholar
• Aman, M. J., Rudolf, G., Goldschmitt, J., Peschel, C. et al. (1993). Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood, 82, 2371–2378.
   PubMed Web of Science ®Google Scholar
• Peschel, C., Aulitzky, W. E. and Huber, C. (1996). Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment: impact on treatment of myeloproliferative disorders. Leuk Lymphoma, 22, (Suppl. 1), 129–134.
   PubMedGoogle Scholar
• Estrov, Z., Markowitz, A. B., Kurzrock, R., Talpaz, M. et al. (1993). Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia, 7, 214–220.
   PubMed Web of Science ®Google Scholar
• Feinstein, E., Climino, G., Gale, R. P. and Canaani, E. (1992). Initiation and progression of chronic myelogenous leukemia. Leukemia, (Suppl. 1), pp. 37–43.
   Google Scholar
• Wetzler, M., Kurzrock, R., Lowe, D. G., Kantarjian, H. M., Gutterman, J. U. and Talpaz, M. (1991). Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. Blood, 78, 2400–2406.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., O'Brien, S., Anderlini, P. and Talpaz, M. (1996). Treatment of chronic myelogenous leukemia: current status and investigation options. Blood, 87, 3069–3081.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., O'Brien, S. et al. (1995). Prolonged survival in chronic myelogenous leukemia following cytogenetic response to alpha interferon therapy. Ann. Int. Med., 122, 254.
   PubMed Web of Science ®Google Scholar
• Alimena, G. and Morra, E. (1989). Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: A study of 82 patients treated with intermitted or daily administration. Blood, 72, 642.
   Web of Science ®Google Scholar
• Ozer, H., George, S., Schiffer, C. et al. (1993). Prolonged subcutaneous administration of recombinant alpha-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and leukemia Group B Study 8583. Blood, 82, 2975.
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994). Interferon alpha-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Eng. J. Med., 330, 820–825.
   PubMed Web of Science ®Google Scholar
• Allan, N. C., Richards, S. M. and Shepherd, P. C. A. (1995). UK medical research council randomized, Multicenter trial of interferonanl for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet, 345, 1392–1397.
   PubMed Web of Science ®Google Scholar
• Koke, O., Niederle, N., Qiu, J. Y. et al. (1993). Impact of interferon-alpha induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br. J. Haematol., 83, 399–403.
   PubMed Web of Science ®Google Scholar
• Ohnishi, K., Ohno, R., Tomonga, M. et al. (1995). A randomized trial comparing interferon alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood, 86, 906–916.
   PubMed Web of Science ®Google Scholar
• Hehlamann, R., Heimpel, H., Hasford, J. et al. (1994). Randomized comparison of interferon alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood, 84, 4064–4077.
   PubMed Web of Science ®Google Scholar
• Chronic Myeloid Leukemia Trialists' Collaboratiov Group (1997). Interferon Alfa versus chemotherapy for Chronic Myeloid Leuekemia: a meta-analysis of sever randomized trials. J. Nal. Cancer Inst., 89, 1616–1620.
   PubMedGoogle Scholar
• Schofield, J., Robinson, W., Murphy, J. and Rovira, D. (1994). Lower doses of interferon alpha are as effective as higher doses in inducing remission and prolonging survival in chronic myeloid leukemia. Ann. Intern. Med., 121, 736.
   PubMed Web of Science ®Google Scholar
• O'Brien, S., Kantarjian, H. M. and Talpaz, M. (1996). Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. Leuk. Lymphoma., 23, 247–252.
   PubMed Web of Science ®Google Scholar
• Sokal, J., Leong, S. and Gomez, G. (1987). Preferential inhibition by cytarabine of CFU-GM from patients from patients with chronic granulocytic leukemia. Cancer, 59, 197.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H., Keating, M., Estey, E. et al. (1992). Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon alpha and low dose cytarabine. J. Clin. Oncol., 10, 772.
   PubMed Web of Science ®Google Scholar
• Arthur, C. K. and Ma, D. D. F. (1993). Combined interferon alfa-2a and cytosine arabinoside as firstline treatment for chronic myeloid leukaemia. Acta Haematol., 89, (Suppl. 1), 15.
   PubMed Web of Science ®Google Scholar
• Gilhout, F., Lamagnere, J., Harousseau, J. et al. (1991). A multicenter study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukemia: Interferon alfa-2b and hydroxyurea with or without cytosine arabinoside, preliminary results. Eur. J. Cancer, 27, (Suppl. 4), S26.
   PubMedGoogle Scholar
• Kantarjian, H., O'Brien, S., Keating, M. and Talpaz, M. (1997). Interferon alpha and low-dose cytosine arabinoside therapy in Philadelphia chromosome-positive chronic myelogenous leukemia. Proceedings of ASCO 1997, 16, 13a.(Abstract).
   Google Scholar
• Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Tanzer, J. et al. (1997). Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. New Eng. J. Med., 337, 223–229.
   PubMed Web of Science ®Google Scholar
• Ilhan, O., Ozcan, M., Yalcin, A., Koc, H., Beksac, M., Unal, A., Tunali, A. et al. (1997). Hematological and cytogenetic efficiency of interferon-a2a plus low-dose cytarabine in chronic myelogenous leukemia: an interim analysis of a multicenter study. Blood, 90, (Suppl. 1), 278b.(Abstract).
   Google Scholar
• Giralt, S., Kantarjian, H. M., Talpaz, M., Champlin, R. et al. (1993). Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J. Clin. Oncol., 11, 1055–1061.
   PubMed Web of Science ®Google Scholar
• Beelan, D. W., Graeven, U., Elmaagacli, A. H. et al. (1995). Prolonged administration of interferon-a in patients with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood, 85, 2981.
   PubMed Web of Science ®Google Scholar
• Horowitz, M. M., Giralt, S., Szyldo, R. et al. (1996). Effect of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia in first chronic phase. Blood, 88, 682a.(Abstract).
   PubMed Web of Science ®Google Scholar
• Shepherd, P., Richards, S. and Allan, N. (1995). Survival after allogeneic bone marrow transplantation (BMT) in patients randomized into a trial of IFN-A versus chemotherapy: No significant adverse effect of prolonged IFN-A administration. Blood, 86, 94a. (Abstract).
   Web of Science ®Google Scholar
• Hehlmann, R., Kolb, H. J., Berger, U. et al. (1997). Influence of pretransplant treatment on survival after allogeneic bone marrow transplantation in CML. Blood, 90, (Suppl.), 228a.(Abstract).
   Google Scholar
• Morton, A. J., Gooley, T., Hansen, J. A., Appelbaum, F. R. et al. (1997). Impact of pre-transplant interferon alpha on outcome of untreated donor marrow transplants for chronic myeloid leukemia in first chronic phase. Blood, 90, (Suppl. 1) (Abstract 536).
   Google Scholar
• Morra, E., Alimena, G., Lazzarino, M. et al. (1991). Evolving modalities of treatment with interferon alfa-2b for Ph-positive chronic myelogenous leukemia. Eur. J. Cancer, 27, (Suppl. 4), 14–17.
   PubMed Web of Science ®Google Scholar
• Fefer, A., Cheever, M. A. and Thomas, E. D. (1979). Disappearance of Ph-pos cells in four patients with chronic myelogenous leukemia following chemotherapy, irradiation and marrow transplantation for an identical twin. N. Eng. J. Med., 300, 331–337.
   Web of Science ®Google Scholar
• Champlin, R. and McClave, P. (1994). Allogeneic bone marrow transplantation for chronic myeloid leukemia. In: Forman, S. J., Blume, K. G. and Thomas, E. D. Eds., Bone marrow transplantation, Boston. Blackwell Scientific Publications, pp. 595–606.
   Google Scholar
• Gratwohi, A., Hermans, J., Niederwieser, D. et al. (1993). Bone marrow transplantation for chronic myeloid leukemia: Long term results. Bone Marrow Transplant, 12, 509–516.
   PubMed Web of Science ®Google Scholar
• Biggs, J. C., Szer, J., Crilley, P. et al. (1992). Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood, 80, 1352–1357.
   PubMed Web of Science ®Google Scholar
• Clift, R. A., Buckner, C. D., Applbaum, F. R. et al. (1991). Allogeneic bone marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimesn. Blood, 77, 1660–1665.
   PubMed Web of Science ®Google Scholar
• Clift, R. A., Buckner, C. D., Thomas, E. D. et al. (1994). Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood, 84, 2036–2043.
   PubMed Web of Science ®Google Scholar
• Goldman, J. M., Gale, R. P., Horowitz, M. M. et al. (1988). Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Ann. Intern. Med., 108, 806–814.
   PubMed Web of Science ®Google Scholar
• Speck, B., Bortin, M. M., Champlin, R. et al. (1984). Allogeneic bone marrow transplantation for chronic myelogenous leukemia. Lancet; i, 665–668.
   Google Scholar
• Thomas, E. D., Clift, R. A., Fefer, A. et al. (1986). Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann. Intern. Med., 104, 155–163.
   PubMed Web of Science ®Google Scholar
• Wagner, J. E., Zahurak, M., Piantadosi, S. et al. (1992). Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits. J. Clin. Oncol., 10, 779–789.
   PubMed Web of Science ®Google Scholar
• Clift, R. A. and Storb, R. (1996). Marrow transplantation for CML: The Seattle experience. Bone Marrow Transplant, 17, (Suppl. 3), 1–3.
   PubMedGoogle Scholar
• Gratwohl, A. and Hermans, J. (1996). Allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant, 17, (Suppl. 3), 7–9.
   PubMed Web of Science ®Google Scholar
• Goldman, J. M., Szydlo, R., Horowits, M. M. et al. (1993). Choice of pre-transplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood, 82, 2235–2238.
   PubMed Web of Science ®Google Scholar
• Clift, R. A., Appelbaum, F. R. and Thomas, E. D. (1993). Treatment of chronic myeloid leukemia by bone marrow transplantation. Blood, 82, 1954–1956.
   PubMed Web of Science ®Google Scholar
• Snyder, D. S., Negrin, R. S., O'Donnel, M. R. et al. (1994). Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood, 84, 1672–1674.
   PubMed Web of Science ®Google Scholar
• Marmont, A. M., Horowitz, M. M., Gale, R. P. et al. (1991). T-cell depletion of HLA-identical transplants in leukemia. Blood, 78, 2120–2130.
   PubMed Web of Science ®Google Scholar
• Scattenberg, A., De Witte, T., Preijers, F. et al. (1990). Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. Blood, 75, 1356–1363.
   PubMed Web of Science ®Google Scholar
• Korbling, M., Przepiorka, D., Engel, H. et al. (1995). Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood, 85, 1659.
   PubMed Web of Science ®Google Scholar
• Giralt, S., Cohen, A., Champlin, R. et al. (1997). Preliminary results of fludarabine/melphalan or 2CDA/melphalan (2CDA/M) as preparative regimens for allogeneic progenitor cell transplantation (ALLO PCT) in poor candidates for conventional myeloblative conditioning. Blood, 90, (Suppl. 1), 417a.(Abstract).
   Google Scholar
• Turhan, A. G., Humphries, R. K., Evans, C. J. et al. (1990). Detection of breakpoint cluster region negative and non-clonal hemopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow. Blood, 81, 543–550.
   Google Scholar
• McGlave, P., Mamus, S., Vilen, B. and Dewald, G. (1987). Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. Exp. Hematol., 15, 331–335.
   PubMed Web of Science ®Google Scholar
• Verfaillie, C. M., Miller, W. J., Boylan, K. and McGlave, P. B. (1992). Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood, 79, 1003–1010.
   PubMed Web of Science ®Google Scholar
• Hoyle, C., Gray, R. and Goldman, J. (1994). Autografting for patients with CML in chronic phase: an update. Br. J. Haematol., 86, 76–81.
   PubMed Web of Science ®Google Scholar
• Carlo-Stella, C., Mangoni, L. and Piovani, G. (1991). In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte-macrophage colony-stimulating factor. Bone Marrow Transplant, 8, 265–273.
   PubMed Web of Science ®Google Scholar
• Reiffers, J., Trouette, R., Marit, G. et al. (1991). Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases. Br. J. Haematol., 77, 339–345.
   PubMed Web of Science ®Google Scholar
• DeFabritiis, P., Sandrelli, A., Melone, G. et al., Prolonged suppression of chronic myeloid progenitor cell numbers after stopping interferon treatment for CML may necessitate delay in harvesting marrow cells for autografting. Bone Marrow Transplant, 6, 247–251.
   PubMed Web of Science ®Google Scholar
• Barnett, M. J., Eaves, C. J., Phillips, G. L. et al. (1989). Successful autografting in chronic myeloid leukemia after maintenance of marrow in culture. Bone Marrow Transplant, 4, 345.
   PubMed Web of Science ®Google Scholar
• McGlave, P. B., Arthur, D., Miller, W. J., Lasky, L. and Kersey, J. (1990). Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant, 6, 115–120.
   PubMed Web of Science ®Google Scholar
• Haines, M. E., Goldman, J. M., Worsely, A. M., McCarthy, D. M. et al. (1984). Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: Probable prolongation of survival for some patients. Br. J. Haematol., 58, 711.
   PubMed Web of Science ®Google Scholar
• Carella, A. M., Pollicardo, N., Pungolino, E. et al. (1993). Mobilization of cytogenetically ‘normal’ blood progenitor cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia. Leukemia Lymphoma, 9, 477–483.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., Talpaz, M., LeMaistre, C. F. et al. (1991). Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. Cancer, 67, 2959–2965.
   PubMed Web of Science ®Google Scholar
• Brito-Babapulle, F., Bowcock, S. J., Marcus, R. E. et al. (1989). Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. Br. J. Haematol., 73, 76–81.
   PubMed Web of Science ®Google Scholar
• Talpaz, M., Kantarjian, H., Liang, J. et al. (1995). Percentage of Philadelphia (Ph) chromosome-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on the percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood, 85, 3257–3263.
   PubMed Web of Science ®Google Scholar
• Reiffers, J., Goldman, J., Meloni, G., Cahn, J. Y. and Gratwohl, A. (1994). Autologous stem cell transplantation in chronic myelogenous leukemia: A retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant, 14, 407.
   PubMed Web of Science ®Google Scholar
• Deisseroth, A., Zu, Z. and Claxton, D. (1994). Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation in CML. Blood, 83, 3068–3073.
   PubMed Web of Science ®Google Scholar
• Degliantoni, G., Mangoni, N. and Rizzoli, V. (1985). In vitro restoration of polyclonal hematopoiesis in a chronic myelogenous leukemia after in vitro treatment with 4-hydroperoxycydophosphamide. Blood, 65, 753.
   PubMed Web of Science ®Google Scholar
• McGlave, P., Miller, J., Miller, W., Perry, E., Fautsch, S., Ramsay, N. K. C. et al. (1994). Autologous marrow transplant therapy for CML using marrow treated exvivo with human recombinant interferon gamma. Blood, 84, 537. (Suppl. 1) (Abstract).
   Google Scholar
• Coulombel, L., Kalousek, D. K., Eaves, C. J., Gupta, C. M. and Eaves, A. C. (1983). Long term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N. Eng. J. Med., 306, 1493.
   Web of Science ®Google Scholar
• Korbling, M., Burke, P., Braine, H., Elfenbein, G., Santos, G. and Kaizer, H. (1981). Successful engraftment of blood derived stem cells in chronic myelogenous leukemia. Exp. Hematol., 9, 684.
   PubMed Web of Science ®Google Scholar
• Carella, A. M., Frassoni, F., Podesta, M., Pungolino, E., Pollicardo, N., Ferrero, R. and Soracco, M. (1994). Idarubicin containing regimen and G-CSF are able to recruit a high rate of normal progenitor cells during early hematopoietic recovery in patients with CML. J. Hematother., 3, 199.
   PubMedGoogle Scholar
• Talpaz, M., Kantarjian, H., Liang, J. et al. (1995). Percentage of Philadelphia chromosome (Ph)-negative and Ph positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional -dose chemotherapy before collection of autologous cells. Blood, 85, 2357.
   Web of Science ®Google Scholar
• McGlave, P. B., De Fabritiis, P., Deisseroth, A., Goldman, J., Barnett, M., Reiffers, J., Siminsson, B., Carella, A. and Aeppli, D. (1994). Autologous transplant for chronic myelogenous leukaemia: Results from eight transplant groups. Lancet, 343, 1486.
   PubMed Web of Science ®Google Scholar
• Szczylik, C., Skorski, T., Nicolaides, N. C. et al. (1991). Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science, 253, 562–565.
   PubMed Web of Science ®Google Scholar
• Mahon, F. X., Belloc, F., Barbot, C. et al. (1992). Chronic myelogenous leukemia: in vitro study with antisense oligomers. Blood, 80, (Suppl. 1). (Abstarct 211).
   Google Scholar
• Martiat, P., Lewalle, P., Taj, A. S. et al. (1993). Retrovirally transduced antisense sequences stably suppress p210BCR/ABL and inhibit the proliferation of BCR/ABL containing cell lines. Blood, 81, 502–509.
   PubMed Web of Science ®Google Scholar
• Ratajczak, M. Z., Hijiya, N., Catani, L. et al. (1992). Acute and chronic-phase chronic myelogenous leukemia colony-forming emits are highly sensitive to the growth inhibitory effects of c-myb antisense oligo-deoxynucleotides. Blood, 79, 1956–1961.
   PubMed Web of Science ®Google Scholar
• Shore, S. K., Nabissa, P. M. and Reddy, E. P. (1993). Ribozyme-mediated cleavage of the bcr-abl oncogene transcript: In vitro cleavage of RNA and in vivo loss of p210 protein kinase activity. Oncogene, 8, 3183.
   PubMed Web of Science ®Google Scholar
• Synder, D. S., Wu, Y., Wang, J. L., Rossi, J. J., Swiderski, P., Kaplan, B. E. and Forman, S. J. (1993). Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome positive cell line. Blood, 82, 600.
   PubMed Web of Science ®Google Scholar
• Leopold, L. H., Shore, S. K., Newkirk, T. A., Reddy, R. M. V. and Reddy, E. P. (1995). Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood, 85, 2162.
   PubMed Web of Science ®Google Scholar
• Okabe, M., Uehara, Y., Miyagishima, T. et al. (1992). Effect of herbimycin A, an antagonist of tyrosine kinase on bcr/abl oncoprotein associated cell proliferations: Abrogative effect on the transformation of muring hematopoietic cells by transfection of a retroviral vector expressing oncoprotein p210bcr/abl and preferential inhibition of Ph-positive leukemia cell growth. Blood, 80, 1330.
   PubMed Web of Science ®Google Scholar
• Kaur, G., Gazit, A., Levitzki, A., Sotwe, E., Cooney, D. A. and Sausville, E. A. (1994). Tyrphostin induced growth inhibition: Correlation with effect on p210bcr/abl autokinase activity in K562 chronic myelogenous leukemia. Anti-Cancer Drugs, 5, 213.
   PubMed Web of Science ®Google Scholar
• Druker, B. J., Tamura, S., Buchdunger, E. et al. (1996). Effects of a selective inhibitor of the abl tyrosine kinase on the growth bcr-abl positive cells. Nat. Med., 2, 561.
   PubMed Web of Science ®Google Scholar
• Verma, U. N., Bagg, A., Brown, E. and Mazumder, A. (1994). Interleukin-2 activation of human bone marrow in long term cultures: An effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant, 13, 115.
   PubMed Web of Science ®Google Scholar
• Verfaillie, C., Miller, W., Kay, N. and McGlave, P. (1989). Adherent lymphokine activated killer cells in chronic myelogenous leukemia: A benign cell population with potent cytotoxic activity. Blood, 74, 793.
   PubMed Web of Science ®Google Scholar
• Verfaillie, C., Kay, N., Miller, W. and McGlave, P. (1990). Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood, 76, 401.
   PubMed Web of Science ®Google Scholar
• Cervantes, F., McGlave, P. B. and Miller, J. S. (1996). Autologous activated natural killer cells (ANK) suppress CML progenitors but spare normal hematopoiesis in long term bone marrow cultures (LTC). Blood, 87, 2476.
   PubMed Web of Science ®Google Scholar
• Bhatia, R. and McGlave, P. B. (1995). T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors. Leukemia, 9, 1006.
   PubMed Web of Science ®Google Scholar
• Miller, S. J., Verfaillie, C. and McGlave, P. B. (1994). Expansion and activation of human natural killer cells as therapy for autologous transplantation. Prog. Clin. Biol. Res., 389, 39.
   PubMedGoogle Scholar
• Verfaillie, C. M., Bhatia, R., Miller, W., Roy, V. et al. (1996). Benign primitive progenitors can be selected on the basis of the CD34+HLA-DR− phenotype in early chronic phase (ECP) but not advanced phase (AP) CML. Blood, 87, 4770.
   PubMed Web of Science ®Google Scholar